M&A activity was down in 2021, but 'mega-mergers' spiked

The number of hospital mergers and acquisitions declined in 2021, however the size of the transactions were larger, according to a new analysis from Kaufman Hall.

Among the factors behind the changes: fewer independent, unaffiliated community hospitals seeking partnerships.

“Organizations are focused on partnerships with a strong strategic rationale and have become increasingly selective in identifying potential partners,” Kaufman Hall said in the report. “They seek partnerships that will have a transformative impact through the addition of new capabilities, enhanced intellectual capital, and access to new markets or services.

Last year had the largest percentage of “mega merger” transactions in the last six years at 16.3%, nearly double the 8.9% in 2020. The eight so-called mega transactions involved sellers or smaller partners with more than $1 billion in annual revenue, according to KH.

In more than 1 out of every 10 transactions, the smaller partner had a credit rating of A- or higher in 2021, according to KH. In that same year, the average annual revenue of these smaller partners was significantly higher compared to 2020 ($619 million vs. $388 million, respectively).

Meanwhile, the role of not-for-profit health systems as both buyers and sellers grew as a percentage of total transactions in 2021, representing 87% of announced transactions, compared with 81% in 2020.

Overall, transactions involving rural or urban/rural sellers increased to 31% of deals, compared to 24% in 2020.

Finally, the number of financially troubled sellers remained flat year-over-year, comprising 16% of announced transactions.

Read the entire analysis here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.